New hope for recurrent cervical cancer: drug cocktail targets HER2

NCT ID NCT07172217

Not yet recruiting Disease control Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests a combination of three drugs—disitamab vedotin, iparomlimab, and tuvonralimab—in 33 women with HER2-expressing recurrent cervical cancer that has progressed after first-line treatment. The goal is to see if the combo can shrink tumors or slow the disease. Researchers will also monitor side effects and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: disitamab vedotin combined with iparomlimab and tuvonralimab
What this could lead to: If successful, this could offer a new second-line treatment option for women with HER2-expressing recurrent cervical cancer, potentially shrinking tumors or slowing disease progression.
What could go wrong: This is a small, early-phase trial with only 33 participants, so results may not apply broadly. The combination therapy may cause side effects, and it is not yet proven to improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT CERVICAL CANCER

Contacts and locations

Locations

Qilu Hospital of Shandong University

Ji'an, Shandong, 250000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.